Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

SEATTLE and CHICAGO, May 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Monday, June 7 at 8:00 a.m. CT.

"With the recent FDA approval of PROVENGE for asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer, patients now have a new treatment option available that prolongs survival," said Daniel P. Petrylak, M.D., program director of the Genitourinary Oncology Section in the Division of Hematology/Oncology at Columbia University.  "Cancer immunotherapy represents an entirely new era in medicine and patient care."

The exploratory analyses include data from three Phase 3 trials in patients with metastatic castrate resistant prostate cancer (Studies D9901, D9902A, and IMPACT) that were integrated to examine the treatment effect in a larger group of patients, the use of docetaxel before and after randomization, and relationships between certain product parameters and clinical outcome.  These include:

  • A poster presentation by Dr. Celestia Higano, professor of oncology and urology at the University of Washington, titled, "Predictors
    '/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
2. Dendreon Announces Pricing of Common Stock Offering
3. Dendreon Appoints Hans Bishop as Chief Operating Officer
4. Dendreon Announces Proposed Public Offering of Common Stock
5. Dendreon Receives FDA Acknowledgement of Complete Response
6. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
7. Dendreon Completes Submission of Biologics License Application for PROVENGE
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
11. Dendreon Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... $28.5 million second tranche of a $40 million investment ... Woodford first invested $25 million in NW Bio ... entered into an agreement with the Company for a ...
(Date:5/1/2015)... , May 1, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has priced an underwritten ... at a price of $9.00 per share, and granted ... purchase up to an additional 585,000 shares of its ... be $35.1 million.  The offering is expected to close on ...
(Date:5/1/2015)... May 1, 2015 /CNW/ - Softchoice, a leading North American IT ... the proud recipient of two Cisco® Partner Summit Country awards. ... the Year and Security Partner of the Year for ... place this week in Montreal . ... two Cisco partner awards at this year,s conference," said ...
(Date:5/1/2015)... , May 1, 2015 ... Genetic Technologies Ltd (NASDAQ: GENE ), Agilent ... Scientific Inc. (NYSE: TMO ), Sequenom Inc. ... PKI ). Free research report on Genetic ... On Thursday, April 30, 2015, the NASDAQ Composite ...
Breaking Biology Technology:NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5
... Here are some troubleshooting hints that we have gathered , if your PCR yields no product:, , , ... , , , ... , , , ... , , , ...
... , , , , , Here are some troubleshooting hints that we have gathered , ... , , , ... , , , ... , , , , ...
... , , , , from rat lung, recombinant, , , , ... Catalog Number, Pack Size, , ... , , 3335402, ... , , , , , Package Inserts/Product , Instructions, ...
Cached Biology Technology:Trouble-shooting: No product 2Trouble-shooting: No product 3Trouble-shooting: No product 4Trouble-shooting: No product 5Trouble-shooting: Non-specific bands 2Trouble-shooting: Non-specific bands 3Trouble-shooting: Non-specific bands 4Trouble-shooting: Non-specific bands 5Trouble-shooting: Non-specific bands 6
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... , This release is available in German ... area of climate research: for decades, scientists have been asking ... dust particles suspended in the atmosphere, enlarge the cloud cover ... no progress on this issue. Two scientists from the Max ...
... a major milestone in its three years of operation, RadMD ... for 150 clinical trials. , The most recent trial, ... was designed to test the efficacy of a new treatment ... support the primary analysis of Progression Free Survival based on ...
... scientists have received grants from the latest round of ... Recovery and Reinvestment Act (ARRA) of 2009. To date, ... million. The recent round of funding includes three highly ... the Challenge Grant competition ― only about 500 were ...
Cached Biology News:Do dust particles curb climate change? 2Do dust particles curb climate change? 3Do dust particles curb climate change? 4RadMD reaches 150th clinical trial 2Forsyth receives highly competitive challenge grants 2
... BMP2 BMP2 belongs to the ... Bone morphogenic protein induces bone formation. ... the autosomal dominant disease of fibrodysplasia ... Synthetic peptide: PSDEVLSEFELRLLSM conjugated to ...
...
... is the successor to the original DS-U1. The ... the cameras in the Nikon DS camera line ... The DS-U2 transmits information at high speed, and ... hub and mass storage USB 2.0 interfaces. The ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
Biology Products: